Christof Vulsteke discusses KEYNOTE-905 results with Ashish Kamat. The phase 3 trial enrolled cisplatin-ineligible muscle-invasive bladder cancer patients, median age 73, receiving perioperative ...
Relugolix is a novel orally administered gonadotropin-releasing hormone (GnRH) antagonist approved for androgen deprivation therapy (ADT) in advanced prostate cancer. Its oral formulation, rapid onset ...
role of Blue Light Cystoscopy in identifying tumors undetected by WLC, Bladder Cancer, Blue Light Cystoscopy for non-muscle-invasive bladder cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback